NK Cell Therapy Patents

Adoptive NK cell therapy patents cover cell-source/manufacturing innovations; CAR-NK/engineering innovations; persistence/armoring innovations; and allogeneic/off-the-shelf and combination/application innovations — with IP held by NK-cell-therapy companies, academia, and pharma (in a field using natural killer cells against cancer). WHY NK CELL THERAPY: NATURAL KILLER (NK) cells are immune cells that kill cancerous and infected cells WITHOUT needing prior antigen 'priming' (unlike T cells), and can be used as a cancer immunotherapy — often ENGINEERED with a CAR (CAR-NK) — as an ALTERNATIVE to CAR-T; NK cells have a pivotal strategic ADVANTAGE: they can be given ALLOGENEICALLY (from a healthy DONOR to ANY patient) WITHOUT causing GRAFT-VERSUS-HOST DISEASE (GvHD) — the dangerous reaction that makes donor T cells unsafe to give across patients — so NK cells enable true OFF-THE-SHELF, mass-produced, banked cell therapy, versus the slow, expensive, custom per-patient process of autologous CAR-T (where each patient's own cells are harvested and engineered); NK cells also have a better SAFETY profile (less cytokine-release syndrome and neurotoxicity than CAR-T); the TRADE-OFFS are that NK cells are HARDER to expand and engineer and PERSIST a shorter time in the body — so persistence and manufacturing are the central challenges. MAJOR HOLDERS: FATE THERAPEUTICS (iPSC-derived NK), NKARTA, NKGEN, SANA, MD ANDERSON (cord-blood CAR-NK), plus pharma. Cell source/manufacturing, CAR-NK/engineering, persistence/armoring, allogeneic/off-the-shelf, and combination/application are the core NK-cell-therapy patent domains — and cell source, engineering, persistence, off-the-shelf manufacturing, and combinations are the open whitespace.

Cell-source/manufacturing innovations; CAR-NK/engineering innovations; gene-editing innovations; and expansion innovations represent core NK-cell patent domains — and where the NK cells come from and how they're engineered are the foundational, high-value capabilities. CELL-SOURCE / MANUFACTURING PATENTS: the SOURCE of the NK cells and how they're made at scale — iPSC-DERIVED NK cells (differentiated from induced pluripotent stem cells — a RENEWABLE, uniform, clonally-engineerable master cell bank, Fate's approach), CORD BLOOD NK (MD Anderson), peripheral-blood NK, and NK-92 cell lines — plus differentiation, expansion, and cryopreservation; cell-source/manufacturing methods are core, high-value IP (the cell SOURCE largely defines the platform — iPSC-derived banks enable uniform, scalable, off-the-shelf product and are a key, defensible asset; manufacturing/expansion is the central scale challenge). CAR-NK / ENGINEERING PATENTS: ENGINEERING NK cells with a CAR (chimeric antigen receptor) or other targeting receptors to direct them at tumor antigens, plus the NK-specific engineering considerations (NK signaling differs from T cells); CAR-NK/engineering methods are core, high-value IP (CAR-NK constructs and NK-optimized signaling domains are distinct from CAR-T IP and a key value/whitespace). GENE-EDITING PATENTS: gene edits to enhance NK function/persistence or knock out inhibitory checkpoints (CRISPR edits, deleting inhibitory receptors); gene-editing methods are high-value IP. EXPANSION PATENTS: methods to robustly EXPAND NK cells to therapeutic numbers (feeder cells, cytokine cocktails) — historically hard for NK; expansion methods are high-value, distinctive IP (NK expansion is a real bottleneck — efficient expansion is valuable). Cell source/manufacturing, CAR-NK/engineering, gene editing, and expansion are the highest-value core IP because a scalable cell source, effective targeting engineering, and robust expansion are exactly what make NK cell therapy work as an off-the-shelf product.

Persistence/armoring innovations; allogeneic/off-the-shelf innovations; combination/application innovations; and safety-switch innovations represent additional NK-cell patent domains — and extending NK lifespan, enabling banked dosing, and combinations are where the central challenges and value lie. PERSISTENCE / ARMORING PATENTS: THE central technical challenge — NK cells PERSIST a much shorter time in the body than T cells, limiting durable responses, so methods to EXTEND persistence and activity — MEMBRANE-BOUND IL-15 (a tethered cytokine that keeps NK cells alive/active without systemic toxicity), cytokine support/autocrine signaling, and 'ARMORING' edits — are critical; persistence/armoring methods are high-value, DISTINCTIVE IP (persistence is the make-or-break for NK efficacy — membrane-bound IL-15 and armoring are among the most valuable, contested NK-cell IP). ALLOGENEIC / OFF-THE-SHELF PATENTS: the core ADVANTAGE — because NK cells don't cause GvHD, they enable BANKED, OFF-THE-SHELF, ANY-PATIENT dosing; methods to manufacture a RENEWABLE off-the-shelf bank (esp. from iPSCs), and to evade host rejection for repeat dosing; allogeneic/off-the-shelf methods are high-value, distinctive IP (off-the-shelf is the whole strategic point versus autologous CAR-T — banked, scalable, immediately-available product is the key commercial advantage and IP). COMBINATION / APPLICATION PATENTS: COMBINING NK cells with monoclonal ANTIBODIES (NK cells mediate ADCC — antibody-directed killing), checkpoint inhibitors, NK-cell ENGAGERS (bispecific molecules bridging NK to tumor), and specific INDICATIONS (hematologic and solid tumors); combination/application methods are high-value IP (NK + antibody/engager combinations are a major, natural synergy and value area). SAFETY-SWITCH PATENTS: safety switches/controls (though NK cells are already safer than T cells); safety-switch methods are valuable IP. Persistence/armoring, allogeneic/off-the-shelf, combination/application, and safety switches are the highest-value application IP because durable persistence, banked off-the-shelf dosing, and synergistic combinations are exactly what make NK cell therapy effective and commercially compelling.

NK cell therapy startup IP strategy must navigate the off-the-shelf-is-the-thesis reality (the whole strategic advantage is allogeneic, no-GvHD, OFF-THE-SHELF, banked therapy versus autologous CAR-T — the cell source/manufacturing (esp. iPSC-derived banks) and off-the-shelf methods are the central IP and value), the persistence-is-the-challenge insight (NK cells are short-lived — persistence/armoring (membrane-bound IL-15, cytokine support) is the make-or-break and most-contested IP), the Fate/Nkarta/MD-Anderson portfolios and CAR-T IP overlap (CAR-NK borrows CAR concepts but NK engineering is distinct — do FTO against both CAR-T and NK IP), the cell-source platform choice (iPSC-derived vs cord-blood vs NK-92 — different IP, scalability, and engineerability; iPSC enables the most scalable, uniform, engineerable bank), the manufacturing/expansion bottleneck (NK expansion and scalable manufacturing are real, valuable challenges), the safety advantage (lower CRS/neurotoxicity is a clinical edge but persistence must deliver efficacy), the combination synergy (NK + antibody/ADCC and NK engagers are natural, high-value combinations), the clinical-efficacy reality (NK therapies must prove durable responses — early efficacy/persistence data are as important as IP), and a landscape where cell source, CAR-NK engineering, persistence, off-the-shelf manufacturing, and combinations are the durable assets; understand that off-the-shelf and persistence define the field, so the durable IP is in cell-source/manufacturing (iPSC banks), CAR-NK/engineering, persistence/armoring, allogeneic/off-the-shelf methods, and combinations — with the iPSC/off-the-shelf platform, persistence solutions, manufacturing, and clinical data often the real moat, and that persistence/efficacy, off-the-shelf scalability, manufacturing, safety, and FTO matter as much as patents; identify whitespace in persistence/armoring, iPSC manufacturing, CAR-NK, and combinations. NK CELL THERAPY STARTUP IP STRATEGY: CELL-SOURCE/iPSC MANUFACTURING, CAR-NK ENGINEERING, PERSISTENCE/ARMORING, OFF-THE-SHELF, AND COMBINATIONS ARE THE IP: patent cell-source/manufacturing (esp. iPSC banks), CAR-NK/engineering, persistence/armoring (membrane-bound IL-15), allogeneic/off-the-shelf methods, and combinations; OFF-THE-SHELF IS THE THESIS: allogeneic, no-GvHD, banked, any-patient therapy is the whole advantage vs autologous CAR-T — the cell source/manufacturing (iPSC banks) and off-the-shelf methods are the central IP and value; PERSISTENCE IS THE CENTRAL CHALLENGE + MOST-CONTESTED IP: NK cells are short-lived — persistence/armoring (membrane-bound IL-15, cytokine support) is the make-or-break and the most valuable, contested IP; CAR-NK OVERLAPS CAR-T IP BUT IS DISTINCT: CAR-NK borrows CAR concepts but NK engineering/signaling is distinct — do FTO against both CAR-T and NK IP; CELL-SOURCE PLATFORM CHOICE (iPSC/CORD/NK-92): iPSC-derived enables the most scalable, uniform, engineerable off-the-shelf bank (Fate) — a key platform decision; MANUFACTURING/EXPANSION IS A REAL BOTTLENECK: NK expansion and scalable manufacturing are hard, valuable challenges; SAFETY IS A CLINICAL EDGE (LOWER CRS/NEUROTOXICITY): NK's safety profile is an advantage — but persistence must deliver durable efficacy; COMBINATIONS (NK + ANTIBODY/ADCC/ENGAGERS) ARE NATURAL SYNERGIES: NK-mediated ADCC and NK engagers are high-value combination IP; PERSISTENCE/EFFICACY/OFF-THE-SHELF/MANUFACTURING/FTO MATTER AS MUCH AS PATENTS: persistence/efficacy, off-the-shelf scalability, manufacturing, safety, and FTO drive value; WHEN TO PATENT: NOVEL SOURCE/ENGINEERING/PERSISTENCE/OFF-THE-SHELF METHOD WITH MEASURED DATA: file once a candidate shows measured results (cell expansion/manufacturing yield + (CAR-NK) tumor killing + in vivo PERSISTENCE/durability + safety (CRS/neurotoxicity) + off-the-shelf bank scalability) — measured persistence, tumor killing, and off-the-shelf manufacturing are the critical NK-cell IP metrics; KEY FTO CHECKLIST: Fate Therapeutics (iPSC-NK)/Nkarta/NKGen/Sana/MD Anderson (cord-blood CAR-NK); CAR-T IP overlap; cell source/manufacturing (iPSC-derived/cord-blood/peripheral/NK-92, differentiation/expansion); CAR-NK/engineering (CAR + NK-optimized signaling); gene editing (CRISPR/inhibitory-receptor knockout); expansion (feeders/cytokines); persistence/armoring (membrane-bound IL-15/cytokine support); allogeneic/off-the-shelf (no-GvHD banked, rejection evasion/repeat dosing); combination/application (antibody-ADCC/checkpoint/NK-engager, heme/solid tumors); safety switch.